SD

Sophos Again Named a Gartner® Peer Insights™ Customers’ Choice for Network Firewalls

Retrieved on: 
Monday, June 5, 2023
Acceleration, Sophos, XGS, TLS, Ford Torino engine specifications, Intelligence, Human voice, Customer, SD, Transport Layer Security, Online shopping, Gartner

OXFORD, U.K., June 05, 2023 (GLOBE NEWSWIRE) -- Sophos, a global leader in innovating and delivering cybersecurity as a service, today announced it has once again been named a Customers’ Choice in the May 2023 Gartner Voice of the Customer for Network Firewalls report. Sophos is recognized as a Customers’ Choice for the second consecutive year, receiving an overall vendor rating of 4.7 out of 5 across 462 verified customer reviews, as of March 31, 2023.

Key Points: 
  • Excellent firewall for the money,” said a network engineer in the services industry
    “SD-WAN enhancements are a very welcome feature in the latest Sophos OS.
  • Sophos Firewall is part of the Sophos Adaptive Cybersecurity Ecosystem , which integrates Sophos’ entire portfolio of products, services and Sophos X-Ops threat intelligence for faster and more contextual and synchronized detection, protection and response.
  • In this Gartner report, vendors with 20 or more eligible published reviews during the specified 18-month submission period are included.
  • Gartner, Voice of the Customer for Network Firewalls, By Peer Contributors, 31 May 2023.

Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
University, Therapy, Progression-free survival, American Society of Clinical Oncology, University of California, Los Angeles, ASCO, Patient, Division, SAN, Annual general meeting, CR, Pembrolizumab, Safety, Society, SD, Pharmaceutical industry, Medicine

SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented safety and efficacy data from the ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors cancer during an oral abstract session on Sunday, June 4 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date.

Key Points: 
  • The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date.
  • Treatment emergent adverse events of Grade ≥3 occurred in 27 (38%) participants and were deemed related to ATRC-101 in 2 (3%).
  • With combination patients included (n=24), disease control was observed in 14 (58%) including 12 (50%) SD, 1 (4%) PR and 1 (4%) CR.
  • Longer progression-free survival was observed in patients with high target expression treated in the 3, 10 and 30 mg/kg dose cohorts.

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

Retrieved on: 
Saturday, June 3, 2023
GIST, Cogent, Sunitinib, Spontaneous bacterial peritonitis, DCR, American Society of Clinical Oncology, Pharmacokinetics, TKI, PEAK, Part, Stromal cell, Associate, PFS, Harvard Medical School, ASCO, Patient, Sarcoma, Annual general meeting, Webcast, CR, SD, APEX, Safety, Society, ORR, Dana–Farber Cancer Institute, Pharmaceutical industry, Fever, Medicine

WALTHAM, Mass. and BOULDER, Colo., June 03, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST). The data are being presented today in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. 

Key Points: 
  • and BOULDER, Colo., June 03, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST).
  • The data are being presented today in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • As of the cutoff date of March 29, 2023, the combination of bezuclastinib and sunitinib was generally well-tolerated with an encouraging safety profile.
  • Cogent is actively enrolling patients in Part 2 of the Phase 3 registration-enabling PEAK trial, which is expected to include approximately 388 second-line, post imatinib GIST patients.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Saturday, June 3, 2023
Pancreatic cancer, CT, PRS, MMAE, Neoplasm, DCR, American Society of Clinical Oncology, RECIST, Trae Elston, CSPC, Shijiazhuang Pharma Group, ASCO, ORR, Publication, Patient, Cancer, Annual general meeting, Mab, ADC, Financial toxicity, DAR, Stomach, Society, SD, Pharmaceutical industry, Vaccine, Medical imaging

NEW YORK, June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Key Points: 
  • These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
  • Elevation Oncology's partner, CSPC, is actively recruiting patients in the Phase 1 clinical trial of SYSA1801 (EO-3021) in China (NCT05009966).
  • "While the study remains ongoing, the responses seen are particularly impressive, especially in the gastric cancer setting in tumors expressing Claudin 18.2.
  • These results are highly informative as Elevation Oncology prepares to initiate a Phase 1 clinical trial of EO-3021 in the US in the second half of 2023."

Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

Retrieved on: 
Saturday, June 3, 2023
CRC, RCC, Affimer, American Society of Clinical Oncology, RECIST, Cancer, USC Norris Comprehensive Cancer Center, Pneumonitis, NK, NSCLC, EDT, Associate, ASCO, Patient, EGFR, Colorectal cancer, Clinical research, Carcinoma, Webcast, Neoplasm, CDT, Society, SD, Safety, Pharmaceutical industry, Communications satellite

The data included 15 evaluable patients and showed encouraging early signs of clinical activity including confirmed partial responses and durable stable disease.

Key Points: 
  • The data included 15 evaluable patients and showed encouraging early signs of clinical activity including confirmed partial responses and durable stable disease.
  • Affimed’s innate cell engager AFM24 aims to reactivate the innate and consequently the adaptive immune system to recognize and destroy EGFR mutant tumors.
  • The Company will provide further details, including data from all three AFM24 monotherapy cohorts, and guidance on the clinical development plan for AFM24 in a conference call and webcast scheduled today.
  • To access the call by phone, please use link:
    https://register.vevent.com/register/BIca5147f060da49d5963a0b00a7bc8a66 and you will be provided with dial-in details and a pin number.

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Retrieved on: 
Saturday, June 3, 2023
Neoplasm, Intensity, Response evaluation criteria in solid tumors, DCR, Survival, Clinical trial, RECIST, Cancer, Royal Marsden Hospital, SHAO, ASCO, Sarcoma, Publication, American Society of Clinical Oncology, Johns Hopkins University, The Royal Marsden NHS Foundation Trust, Patient, TTB, Ipilimumab, Subbiah, Tumor necrosis factor, Scientific Reports, IPI, BMS, Cisplatin, MOS, Pharmacology, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, SD, Food, Pharmaceutical industry, Vinblastine

WESTPORT, Conn., June 3, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Key Points: 
  • Abstract Title: Intratumoral INT230-6 (Cisplatin, Vinblastine, SHAO) alone or with ipilimumab (IPI) prolonged survival with favorable safety in adults with refractory sarcomas [Intensity IT-01; BMS#CA184-592].
  • Sarcoma remains a very challenging cancer to treat and has historically proven resistant to checkpoint blockade.
  • Novel approaches are needed for this patient population, and Intensity's data indicate that sarcoma is an attractive target for intratumoral injection.
  • For the combination arm, one subject had yet to reach the first timepoint for SD at the time of data cut-off.

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Retrieved on: 
Friday, June 2, 2023
Edinburgh, CMAI, Central nervous system, Delirium, Alzheimer's disease, Benzodiazepine, Hypotension, Disease, Tolerability, Eating, Quality of life, IMCA, Falls, Appetite, Doctor of Philosophy, Agitation, Dementia, MD, Mini–Mental State Examination, SD, AD, SCI, Edinburgh Feeding Evaluation in Dementia Scale, Sophie, Pharmaceutical industry, Medical imaging, Safety, Patient

Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.

Key Points: 
  • Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.
  • This Phase IIa clinical trial was an open label  trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and efficacy trends of twice daily oral administration of SCI-110.
  • In general, the trial medication was well tolerated with no negative response to the treatment observed throughout the trial duration.
  • Alzheimer disease' patients experience many different symptoms that deteriorate their condition including lack of appetite, sleep quality and agitation.

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

Retrieved on: 
Friday, June 2, 2023
CD47, PD, GBM, Survival, American Society of Clinical Oncology, Glioblastoma, Trial of the century, ASCO, MDSC, PD-L1, Patient, TME, Decompression (diving), CR, CTL, CD36, Therapy, Tumor microenvironment, Phenotype, Society, SD, Pharmaceutical industry, Cleveland Clinic

VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).

Key Points: 
  • VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).
  • In a phase I/II clinical study in solid tumors (NCT03364400) VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma.
  • Historically, rGBM patients have a response rate of less than 5% and a median progression free survival of 48 days.
  • Title: Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

IMOU launches new outdoor & indoor camera Cruiser 2 & Rex 3D with the latest A.I. algorithms

Retrieved on: 
Friday, June 2, 2023
HD, Darkness, H.265, Internet of things, Rotation, Perception, Duplex (telecommunications), Night vision, Privacy, CNN, Motion, Beauty, Algorithm, Pet, AI, Family, NVR, SD, Pan, GB, Mobile phone, Television, Security printing, Camera, Telescopic sight

HANGZHOU, China, June 2, 2023 /PRNewswire/ -- IMOU, a leading smart IoT solution and service provider, believes that technology and beauty can be integrated, and that smart technology can be presented in an visually-appealing way. Today it launches Rex 3D and Cruiser 2 as the first smart pan & tilt smart indoor and outdoor security camera that equipped with IMOU SENSE™, which is self-developed AI algorithm matrix by IMOU.

Key Points: 
  • Today it launches Rex 3D and Cruiser 2 as the first smart pan & tilt smart indoor and outdoor security camera that equipped with IMOU SENSE™, which is self-developed AI algorithm matrix by IMOU.
  • Based on the powerful AI algorithm of IMOU SENSE™, Rex 3D and Cruiser 2 have a recognition accuracy of 99% for human figures and pets.
  • Rex 3D and Cruiser 2 provide more accurate detection results and can effectively filter out false alarms.
  • Rex 3D and Cruiser 2 have two levels of image quality, 3MP and 5MP.

Sony Electronics Announces New High-Performance M Series CFexpress Type A Memory Cards CEA-M1920T and CEA-M960T

Retrieved on: 
Thursday, June 1, 2023
CFexpress, Sony, XAVC, USD, VPG, SAN, Water, Dust, Data-rate units, Environment, RAW, SD, GB, Computer data storage

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Today, Sony announced two new CEA-M Series CFexpress Type A memory cards, CEA-M1920T and CEA-M960T, that conform to the CFexpress 2.0 and VPG200 and offer high 1920 GB and 960 GB capacities. In addition to a VPG200 rating that guarantees fast and stable video recording without dropped frames, they are resistant to bending and drop impact and feature a dust and moisture sealing that ensures maximum reliability in any environment. These compact, high-performance memory cards are ideal for professional users who need high capacities and stress-free, reliable operation.

Key Points: 
  • SAN DIEGO, June 1, 2023 /PRNewswire/ -- Today, Sony announced two new CEA-M Series CFexpress Type A memory cards, CEA-M1920T and CEA-M960T, that conform to the CFexpress 2.0 and VPG200 and offer high 1920 GB and 960 GB capacities.
  • These compact, high-performance memory cards are ideal for professional users who need high capacities and stress-free, reliable operation.
  • Despite their large capacities, these CFexpress Type A memory cards are very compact, about half the size of Type B cards, and even shorter and narrower than SD cards.
  • Sony's free desktop applications support protecting important data in the CFexpress Type A cards: Media Scan Utility diagnoses the state of the flash memory in memory cards, and Memory Card File Rescue recover accidentally deleted image data on memory cardsiv v. RAW images and 4K movie data are supported.